Hepatocellular carcinoma

Nature Reviews Disease Primers, Journal Year: 2021, Volume and Issue: 7(1)

Published: Jan. 21, 2021

Language: Английский

---

Mechanisms of NAFLD development and therapeutic strategies

Nature Medicine, Journal Year: 2018, Volume and Issue: 24(7), P. 908 - 922

Published: June 29, 2018

Language: Английский

---

Burden of liver diseases in the world

Journal of Hepatology, Journal Year: 2018, Volume and Issue: 70(1), P. 151 - 171

Published: Sept. 26, 2018

Language: Английский

---

Non-alcoholic fatty liver disease

The Lancet, Journal Year: 2021, Volume and Issue: 397(10290), P. 2212 - 2224

Published: April 21, 2021

Language: Английский

---

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

Journal of Hepatology, Journal Year: 2019, Volume and Issue: 71(4), P. 793 - 801

Published: July 4, 2019

Language: Английский

---

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Hepatology, Journal Year: 2018, Volume and Issue: 69(6), P. 2672 - 2682

Published: Sept. 4, 2018

Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown to most common cause of chronic in world. In fact, 25% world’s population is currently thought have NAFLD. Nonalcoholic steatohepatitis (NASH) subtype NAFLD that can progress cirrhosis, hepatocellular carcinoma (HCC), and death. NASH are not only found adults—there also high prevalence these diseases children adolescents. Because close association with type diabetes (T2DM) obesity, latest models predict will increase, causing tremendous clinical economic burden poor patient‐reported outcomes. Nonetheless, there no accurate noninvasive method detect NASH, treatment this limited lifestyle modifications. To examine state among different regions understand global trajectory disease, an international group experts came together during 2017 American Association for Study Liver Diseases Global Forum. We provide summary forum assessment current worldwide.

Language: Английский

---

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Journal of Hepatology, Journal Year: 2018, Volume and Issue: 69(4), P. 896 - 904

Published: June 7, 2018

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis hepatocellular carcinoma globally. This burden is expected to increase as epidemics obesity, diabetes metabolic syndrome continue grow. The goal this analysis was use Markov model forecast NAFLD using currently available data.A used estimate NASH progression in eight countries based on data for adult prevalence obesity type 2 mellitus (DM). Published estimates expert consensus were build validate the projections.If DM level off future, we project modest growth total cases (0-30%), between 2016-2030, with highest China result urbanization lowest Japan shrinking population. However, at same time, will 15-56%, while mortality advanced more than double an aging/increasing population.NAFLD represent large growing public health problem efforts understand epidemic mitigate needed. If current historical rates, both increase. Since reversible, campaigns awareness diagnosis, promote diet exercise can help manage future burden.Non-alcoholic lead disease. Both conditions becoming prevalent A mathematical built how associated change over time. Results suggest increasing liver-related coming years.

Language: Английский

---

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Hepatology, Journal Year: 2023, Volume and Issue: 77(4), P. 1335 - 1347

Published: Jan. 3, 2023

Background and Aims: NAFLD is a leading cause of liver-related morbidity mortality. We assessed the global regional prevalence, incidence, mortality using an in-depth meta-analytic approach. Approach Results: PubMed Ovid MEDLINE were searched for population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA). Meta-analysis was conducted random-effects models. Bias risk assessment Joanna Briggs Institute. Of 2585 reviewed, 92 (N=9,361,716) met eligibility criteria. Across study period (1990–2019), pooling prevalence estimates ultrasound-defined yielded overall 30.05% (95% CI: 27.88%–32.32%) 30.69% (28.4–33.09), respectively. Global increased by +50.4% 25.26% (21.59–29.33) in 1990–2006 38.00% (33.71–42.49) 2016–2019 ( p <0.001); +38.7% 25.16% (19.46–31.87) 34.59% (29.05–40.57) =0.029). The highest Latin America 44.37% (30.66%–59.00%), then Middle East North Africa (MENA) (36.53%, 28.63%–45.22%), South Asia (33.83%, 22.91%–46.79%), South-East (33.07%, 18.99%–51.03%), (31.20%, 25.86%–37.08%), (29.71%, 25.96%–33.76%), Pacific 28.02% (24.69%–31.60%), Western Europe 25.10% (20.55%–30.28%). Among cohort diagnosed without liver biopsy, pooled rate 1000 PY 12.60 (6.68–23.67) all-cause mortality; 4.20 (1.34–7.05) cardiac-specific 2.83 (0.78–4.88) extrahepatic cancer-specific 0.92 (0.00–2.21) liver-specific Conclusions: 30% increasing which requires urgent comprehensive strategies raise awareness address all aspects on local, regional, levels.

Language: Английский

---

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2020, Volume and Issue: 18(4), P. 223 - 238

Published: Dec. 21, 2020

Language: Английский

---

Mechanisms and disease consequences of nonalcoholic fatty liver disease

Cell, Journal Year: 2021, Volume and Issue: 184(10), P. 2537 - 2564

Published: May 1, 2021

Language: Английский

---